Sensible Bio
Sensible Bio accelerates the development of next-generation mRNA medicines by pioneering a novel manufacturing paradigm that produces non-immunogenic, highly pure, and functional mRNA. By building critical biomanufacturing infrastructure, Sensible Bio enhances scalability, consistency, and global biosecurity, enabling the rapid production of life-saving therapeutics and vaccines.
Founders
I am CEO and Co-Founder of Sensible Biotechnologies, where we’re building a platform to produce high-quality mRNA, while removing complex supply chain bottlenecks. Our mission is to unlock the full potential of mRNA technology, enabling the next generation of therapeutics and vaccines while strengthening global biomanufacturing infrastructure. We've raised over $10M from top-tier US and European life science and deep tech investors such as Y Combinator, Recode Ventures and BlueYard Capital, and secured multiple a strategic partnership with multiple private and public companies.